8-K: Monogram Technologies Announces Third Quarter 2024 Results and $13 Million Public Offering

Monogram Technologies reported its Q3 2024 financial results, highlighted by a $13 million public offering and progress on FDA clearance for its mBs TKA System.

Summary

• Monogram Technologies announced its financial results for the third quarter of 2024, ending September 30th.
• The company successfully closed an upsized and oversubscribed $13 million public offering.
• They submitted a 510(k) premarket filing to the FDA for their semi-active mBs TKA System, which passed the initial administrative review.
• An Additional Information Request (AIR) was received from the FDA, placing the application on hold pending a response within 180 days.
• Monogram secured a strategic collaboration with Shalby Limited in India for a multicenter clinical trial of the mBs TKA System.
• The company was named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.
• Research and development expenses decreased to $2.2 million from $2.7 million in the prior-year quarter.
• Marketing and advertising expenses increased significantly to $1.8 million from $32,220 in the prior-year quarter due to a marketing campaign for the Series D preferred stock offering.
• The net loss for the quarter was $5.0 million, compared to a $1.0 million loss in the same quarter of the previous year.
• Cash and cash equivalents totaled $16.6 million as of September 30, 2024, up from $13.6 million at the end of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful capital raise and progress with the FDA submission, but tempered by the delay caused by the AIR and increased losses.

Positives

• The successful $13 million public offering provides a cash runway for near-term commercialization milestones.
• The strategic collaboration with Shalby Limited will facilitate clinical trials and international expansion.
• The company's recognition as Orthopedic Joint Replacement Company of the Year 2024 highlights its potential.
• The company has $16.6 million in cash and cash equivalents.

Negatives

• The FDA's Additional Information Request (AIR) has placed the 510(k) application on hold.
• The net loss for the quarter increased to $5.0 million from $1.0 million in the prior-year quarter.
• Marketing and advertising expenses increased significantly to $1.8 million from $32,220 in the prior-year quarter.

Risks

• The company's ability to respond to the FDA's Additional Information Request (AIR) within 180 days is critical for the 510(k) clearance.
• The outcome of the issue-specific meeting with the FDA in December could impact the timeline for addressing the AIR.
• The company's lack of profitability and need for additional capital to grow its business is a risk.
• The company is dependent on partners to further the development of its product candidates.
• There are uncertainties inherent in the development, regulatory approvals, and launch of any new product.

Future Outlook

The company is focused on responding to the FDA's AIR, obtaining clearance for its 510(k) submission, conducting clinical trials in India, and exploring further domestic and international relationships as it moves toward commercialization.

Management Comments

• The third quarter was highlighted by an upsized and oversubscribed $13 million public offering and continued progress toward clearance for the semi-active version of the mBs TKA System with the FDA, said Ben Sexson, Chief Executive Officer of Monogram.
• Funds from the offering are expected to provide the cash runway to meet near-term commercialization milestones and resources to support key initiatives, including clinical trials and further development of our technology.
• We are also working to obtain FDA clearance for our 510(k) submission.
• We believe this response provides more transparency for our path forward.
• We are highly focused on the response to the AIR and trying to obtain FDA clearance of our 510(k) submission as quickly and economically as possible.
• We look forward to additional updates in the weeks and months to come as we execute on our upcoming milestones.

Industry Context

This announcement is relevant to the orthopedic robotics industry, where companies are striving to develop advanced surgical systems. Monogram's progress with its mBs TKA System and its collaboration with Shalby Limited are significant steps in this competitive landscape.

Comparison to Industry Standards

• The FDA's request for additional information on 68% of 510(k) applications in FY2022, as mentioned in the document, is a common hurdle for medical device companies, including competitors like Stryker, Zimmer Biomet, and Medtronic.
• Monogram's collaboration with Shalby Limited is similar to other medical device companies partnering with hospitals for clinical trials, such as Globus Medical's partnerships with various institutions.
• The $13 million public offering is a common method for funding development and commercialization, similar to capital raises by companies like Smith+Nephew and NuVasive.
• Monogram's focus on AI-driven robotics aligns with the industry trend towards advanced technologies in orthopedic surgery, as seen in the development of robotic systems by companies like Intuitive Surgical and Mazor Robotics (now part of Medtronic).

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the FDA application.
• Employees will be affected by the company's ability to execute its plans and secure regulatory approvals.
• Customers (surgeons and hospitals) will be interested in the progress of the mBs TKA System and its potential benefits.
• Suppliers will be impacted by the company's production and commercialization plans.
• Creditors will be interested in the company's financial stability and ability to repay debts.

Next Steps

• The company will hold an issue-specific meeting with the FDA by December 2024.
• They will seek regulatory clearance to conduct clinical trials in India with Shalby Hospitals.
• The company plans to conduct OUS live-patient surgery trials and submit clinical trial data to the FDA.
• They will continue exploring domestic and international relationships.
• The company will be exhibiting at Arab Health in January 2025.

Key Dates

Keywords

Orthopedic Surgery, Robotics, FDA Clearance, 510(k), Clinical Trials, mBs TKA System, Public Offering, AI, Shalby Limited, Medical Technology